IKK-ε Antibody (E-2): sc-374546
- IKK-ε Antibody (E-2) is a mouse monoclonal IgG2b κ provided at 200 µg/ml
- specific for an epitope mapping between amino acids 691-716 at the C-terminus of IKK-ε of mouse origin
- recommended for detection of IKK-ε of mouse and rat origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP and m-IgG2b BP-HRP are the preferred secondary detection reagents for IKK-ε Antibody (E-2) for WB applications. These reagents are now offered in bundles with IKK-ε Antibody (E-2) (see ordering information below).
QUICK LINKS
IKK-ε Antibody (E-2) is a mouse monoclonal IgG2b antibody that detects IKK-ε in mouse and rat samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). IKK-ε, also known as IKBKE, is a serine/threonine kinase that plays a crucial role in the immune response by regulating the activation of the transcription factor NFκB. IKK-ε is primarily expressed in immune cells and is induced by stimuli such as lipopolysaccharide and proinflammatory cytokines, including TNFα, IL-1, and IL-6. IKK-ε phosphorylates IκBα at specific serine residues, leading to IκB degradation and subsequent activation of NFκB, which is essential for the transcription of genes involved in inflammation and immune responses. The interaction of IKK-ε with IκBα highlights a pivotal role in modulating cellular signaling pathways that are critical for maintaining immune homeostasis and responding to pathogenic challenges. Anti-IKK-ε antibody (E-2) serves as an invaluable tool for researchers studying the mechanisms of immune regulation and the pathophysiology of inflammatory diseases.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
IKK-ε Antibody (E-2) References:
- IKKε modulates RSV-induced NF-κB-dependent gene transcription. | Bao, X., et al. 2010. Virology. 408: 224-31. PMID: 20961594
- The non-canonical IκB kinases IKKε and TBK1 as potential targets for the development of novel therapeutic drugs. | Niederberger, E., et al. 2013. Curr Mol Med. 13: 1089-97. PMID: 23157677
- Targeting HER2(+) breast cancer: the TBK1/IKKε axis. | Jiang, Z., et al. 2014. Oncoscience. 1: 180-2. PMID: 25594009
- IKKε and TBK1 expression in gastric cancer. | Lee, SE., et al. 2017. Oncotarget. 8: 16233-16242. PMID: 27145266
- Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor. | Lefranc, J., et al. 2020. J Med Chem. 63: 601-612. PMID: 31859507
- Negative Regulation of IKKε-Mediated IRF7 Phosphorylation by HSP70. | Lee, KJ., et al. 2020. J Immunol. 204: 2562-2574. PMID: 32169844
- TBK1/IKKε Negatively Regulate LPS-Induced Neutrophil Necroptosis and Lung Inflammation. | Wang, J., et al. 2021. Shock. 55: 338-348. PMID: 32925605
- FGF21 is required for the metabolic benefits of IKKε/TBK1 inhibition. | Reilly, SM., et al. 2021. J Clin Invest. 131: PMID: 33822771
- Targeting IKKε in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic Instability. | Gilbert, S., et al. 2022. Mol Cancer Ther. 21: 407-418. PMID: 34965959
- ID2 inhibits innate antiviral immunity by blocking TBK1- and IKKε-induced activation of IRF3. | Yu, C., et al. 2022. Sci Signal. 15: eabh0068. PMID: 34982578
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IKK-ε Antibody (E-2) | sc-374546 | 200 µg/ml | $322.00 | |||
IKK-ε Antibody (E-2): m-IgG Fc BP-HRP Bundle | sc-540470 | 200 µg Ab; 10 µg BP | $361.00 | |||
IKK-ε Antibody (E-2): m-IgG2b BP-HRP Bundle | sc-549786 | 200 µg Ab; 10 µg BP | $361.00 | |||
IKK-ε (E-2) Neutralizing Peptide | sc-374546 P | 100 µg/0.5 ml | $69.00 |